ARNA Financial Facts

Loss from operations: -26.21M
Research and development: 24.51M
See Full Income Statement

Acquired technology and other intangibles, net: 8.98M
Accrued clinical and preclinical study fees: 4.49M
See Full Balance Sheet

Arena Pharmaceuticals, Inc. (ARNA) Earnings

  |   Expand Research on ARNA
Next EPS Date 5/12/15 *Est. EPS Growth Rate -36.4% *Last Qtr.
Average EPS % Beat Rate +35.2% Revenue Growth Rate +48.4% *Last Qtr.
Average % Move 1-Wk after EPS -3.6% Normal Earnings Time N/A
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
3/2/15 Q414 -$0.15-$0.12 -$0.03$9.2M$10.36M N/A Details
11/3/14 Q314 -$0.05-$0.12 +$0.07$8.2M$10.9M N/A Details
8/1/14 Q214 $0.03-$0.11 +$0.14$12.8M$9.81M N/A Details
5/12/14 Q114 -$0.12-$0.10 -$0.02$6.8M$7.98M N/A Details
2/27/14 Q413 -$0.11-$0.11 $0.00$6.2M$7M N/A Details
11/7/13 Q313 -$0.08-$0.12 +$0.04$3.6M$5.3M N/A Details
8/1/13 Q213 $0.18$0.15 +$0.03$68.9M$57.3M N/A Details
5/2/13 Q113 $0.09$0.11 -$0.02N/A$50.36M N/A Details